Agenus Announces Closing of Public Offering & Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Com...
May 27 2015 - 3:01PM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immunology company developing
innovative treatments for cancers and other diseases, today
announced the closing of its public offering of 12,650,000 shares
of common stock, offered at a price to the public of $6.30 per
share, which includes the exercise in full by the underwriters of
their option to purchase 1,650,000 additional shares of common
stock. This exercise brings the net proceeds in the offering to
approximately $74.6 million, after deducting underwriting discounts
and commissions and expenses payable by Agenus.
Jefferies LLC and William Blair & Company,
L.L.C. acted as joint book-running managers for the offering,
and Oppenheimer & Co. Inc. acted as co-manager for the
offering.
The securities described above were offered by Agenus pursuant
to a shelf registration statement that was previously filed with
the Securities and Exchange Commission (SEC) on October 10, 2014
and declared effective by the SEC on October 23, 2014. The
securities were offered only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A final prospectus supplement and accompanying
prospectus relating to the offering were filed with the SEC on May
21, 2015 and are available on the SEC’s website at www.sec.gov.
Copies of the final prospectus supplement and accompanying
prospectus may also be obtained by contacting Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by email at
Prospectus_Department@Jefferies.com, or by phone at (877) 547-6340;
or William Blair & Company, L.L.C. at 222 West Adams Street,
Chicago, IL 60606, Attention: Prospectus Department, by telephone
at (800) 621-0687, or by email at prospectus@williamblair.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Agenus
Agenus is an immunology company developing a series of
Checkpoint Modulators for the treatment of patients with cancer,
infectious diseases, and other immune disorders, heat shock protein
(HSP)-based vaccines, and immune adjuvants. These programs are
supported by three separate technology platforms. Agenus’ internal
and partnered checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed programs. The
company’s proprietary discovery engine Retrocyte DisplayTM is
used to generate fully human and humanized therapeutic antibody
drug candidates. The Retrocyte Display platform uses a
high-throughput approach incorporating IgG format human antibody
libraries expressed in mammalian B-lineage cells. Agenus recently
acquired a powerful yeast antibody display platform termed SECANT®,
developed by Celexion, LLC. SECANT allows rapid generation of
soluble, full-length human antibodies. SECANT and Agenus’ mammalian
antibody display platform have complementary strengths and further
bolster Agenus’ abilities to generate and optimize fully human
monoclonal antibodies. Agenus’ heat shock protein-based vaccines
have completed Phase 2 studies in newly diagnosed glioblastoma
multiforme, and in the treatment of herpes simplex viral infection;
the heat shock protein-based vaccine platform can generate
personalized as well as off the shelf products. The company’s QS-21
Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and with Janssen Sciences Ireland UC and includes
several candidates in Phase 2 trials, as well as shingles and
malaria vaccines which have successfully completed Phase 3 clinical
trials.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150527006285/en/
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney, 212-600-1902andrea@argotpartners.comorJamie
Maarten, 212-600-1902jamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024